Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
WVE-007 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Part A: Experimental WVE-007 (Dose 1) or Placebo Part B Pre-T2D: Experimental WVE-007 (Dose 1) or Placebo |
| Cohort 2 | EXPERIMENTAL | Part A: Experimental WVE-007 (Dose 2) or Placebo Part B Pre-T2D: Experimental WVE-007 (Dose 2) or Placebo |
| Cohort 3 | EXPERIMENTAL | Part A: Experimental WVE-007 (Dose 3) or Placebo |
| Cohort 4 | EXPERIMENTAL | Part A: Experimental WVE-007 (Dose 4) or Placebo Part B T2D: Experimental WVE-007 (Dose 4) or Placebo |
| Cohort 5 | EXPERIMENTAL | Part A: Experimental WVE-007 (Dose 5) or Placebo Part B T2D: Experimental WVE-007 (Dose 5) or Placebo |
| Name | Type | Description |
|---|---|---|
| WVE-007 | DRUG | Stereopure siRNA oligonucleotide |
Inclusion Criteria: Part A * Male and female participants aged 18 to 60 years * BMI 28 to 35 kg/m2 which has been stable (±5%) for the previous 3 to 6 months (based on participant self-report or medical records). For participants considered for enrollment in a cohort expansion, BMI 28 to 40 kg/ m2 ...
WVE-007 is an investigational small molecule being developed for the treatment of overweight and obesity. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
WVE-007 targets Activin E, a protein involved in metabolic regulation. By modulating this target, the drug aims to address conditions related to overweight and obesity.
WVE-007 is being developed by Wave Life Sciences Ltd., a biopharmaceutical company listed on the NASDAQ under the ticker symbol WVE.
WVE-007 is in Phase 1 clinical development. It is currently being evaluated in a Phase 1/2a study and has not yet received regulatory approval.
WVE-007 is being studied in a Phase 1/2a trial (NCT06842186) enrolling 296 adults with overweight or obesity. The study is recruiting participants in the United States, Moldova, Romania, and the United Kingdom.